title: A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation.
abstract: BACKGROUND
  Sirolimus is a potent immunosuppressive agent whose role in liver transplantation has not been well-described.
  
  
  OBJECTIVE
  To evaluate the efficacy and side-effects of sirolimus-based immunosuppression in liver transplant patients.
  
  
  METHODS
  Retrospective analysis of 185 patients who underwent orthotopic liver transplantation. Patients were divided into three groups: group SA, sirolimus alone (n = 28); group SC, sirolimus with calcineurin inhibitors (n =56) and group CNI, calcineurin inhibitors without sirolimus (n = 101).
  
  
  RESULTS
  One-year patient and graft survival rates were 86.5% and 82.1% in group SA, 94.6% and 92.9% in group SC, and 83.2% and 75.2% in group CNI (P = N.S.). The rates of acute cellular rejection at 12 months were comparable among the three groups. At the time of transplantation, serum creatinine levels were significantly higher in group SA, but mean creatinine among the three groups at 1 month was similar. More patients in group SA required dialysis before orthotopic liver transplantation (group SA, 25%; group SC, 9%; group CNI, 5%; P = 0.008), but at 1 year, post-orthotopic liver transplantation dialysis rates were similar.
  
  
  CONCLUSIONS
  Sirolimus given alone or in conjunction with calcineurin inhibitors appears to be an effective primary immunosuppressant regimen for orthotopic liver transplantation patients. Further studies to evaluate the efficacy and side-effect profile of sirolimus in liver transplant patients are warranted.
authors.affiliation: Liver Transplant Program, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA.
authors.forename: H
authors.initials: H
authors.lastname: Zaghla
authors.forename: R R
authors.initials: RR
authors.lastname: Selby
authors.forename: L S
authors.initials: LS
authors.lastname: Chan
authors.forename: J A
authors.initials: JA
authors.lastname: Kahn
authors.forename: J A
authors.initials: JA
authors.lastname: Donovan
authors.forename: N
authors.initials: N
authors.lastname: Jabbour
authors.forename: Y
authors.initials: Y
authors.lastname: Genyk
authors.forename: R
authors.initials: R
authors.lastname: Mateo
authors.forename: S
authors.initials: S
authors.lastname: Gagandeep
authors.forename: L S
authors.initials: LS
authors.lastname: Sher
authors.forename: E
authors.initials: E
authors.lastname: Ramicone
authors.forename: T-L
authors.initials: TL
authors.lastname: Fong
mesh_terms: D001772:Blood Cell Count; D065095:Calcineurin Inhibitors; D003404:Creatinine / Q000097:blood; D005260:Female; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000276:immunology; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000503:physiopathology; D008107:Liver Diseases / Q000601:surgery; D016031:Liver Transplantation / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care / Q000379:methods; D012189:Retrospective Studies; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D065095:Calcineurin Inhibitors; D006454:Hemoglobins; D007166:Immunosuppressive Agents; D003404:Creatinine; D020123:Sirolimus